Macimorelin - AEterna Zentaris
Alternative Names: AEZS-130; ARD-07; D-87575; EP-01572; EP-1572; Ghryvelin; JMARD-07; JMV-1843; Macimorelin acetate; Macrilen; SolorelLatest Information Update: 20 Jul 2023
At a glance
- Originator AEterna Zentaris Inc
- Developer AEterna Zentaris Inc; Consilient Health; Novo Nordisk; University of Queensland
- Class Amides; Carboxylic acids; Diagnostic agents; Indoles; Oligopeptides; Small molecules
- Mechanism of Action Ghrelin receptor agonists; Ghrelin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Somatotropin deficiency
Highest Development Phases
- Marketed Somatotropin deficiency
- Phase II Cachexia
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 13 Jul 2023 Aeterna Zentaris plans to have scientific advice meeting with regulatory authorities to discuss next steps program development
- 12 Apr 2023 USPTO has issued a Notice of Allowance for Aeterna’s patent application (US 17 375 709) titled, “Use of Macimorelin in Assessing Growth Hormone Deficiency in Children"
- 12 Apr 2023 AEterna Zentaris intends to temporarily withdraw macimorelin for Somatotropin deficiency (Diagnosis, In adults) in USA from May 2023 until the relaunch with an ulternate commercialization partner (PO)